TVTX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Travere Therapeutics, Inc. had $491M of revenue in fiscal 2025, up 110.5% on the year before. Over five years, revenue changed +19.9% a year on average.
Last close Β· Oct 23, 2026
$50.08
4.5%Hi! I read Travere Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+110.5%
Yes. Sales grew 110.5% last year.
Does it make a profit?
β5.2%
No. It lost money last year.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Travere Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
October 29, 2026
Thursday Β· in 3 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 4, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 4, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '25 | After the market closes | 8-K β |
| Oct 30, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 1, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Jan 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Oct 31, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Travere Therapeutics, Inc. had $491M of revenue in fiscal 2025, up 110.5% on the year before. Over five years, revenue changed +19.9% a year on average. Its operating margin was β12.8%, up 126.1Β pts: of every 100 in sales, about β13 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Travere Therapeutics, Inc. lost $25.5M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Travere Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $428M | $347M | $307M | $58.5M | $238M |
| Interest coverage | β10.1x | β29.1x | β34.3x | β29.0x | β5.8x |
| Current ratio | 4.7x | 3.4x | 3.5x | 2.1x | 2.7x |
| Quick ratio | 4.6x | 3.4x | 3.4x | 1.9x | 2.5x |
| Total assets | $777M | $673M | $789M | $594M | $605M |
| Total liabilities | $475M | $630M | $588M | $535M | $490M |
| Shareholders' equity | $302M | $42.9M | $201M | $59.1M | $115M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Travere Therapeutics, Inc. passes 6 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 2 / 8 | 3 / 8 | 2 / 8 | 4 / 8 | 1 / 8 | 3 / 8 | 3 / 8 | 6 / 8 |
| Accruals ratio | β8.5% | β12.8% | β12.6% | β13.4% | β20.9% | β23.9% | β12.7% | 23.1% | β12.2% | β10.6% |
| Altman Z'' | 3.15 | 2.57 | 2.47 | 0.45 | β1.10 | β0.40 | β4.68 | β3.95 | β9.10 | β5.38 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $134M | $155M | $164M | $175M | $198M | $132M | $109M | $145M | $233M | $491M |
| Net interest income | $4.0M | $3.2M | $5.5M | β | β | β | β | β | β | β |
| Gross profit | $129M | $151M | $159M | $170M | $192M | $128M | $105M | $134M | $225M | $480M |
| Research and development | $70.8M | $78.2M | $124M | $141M | $132M | $201M | $7.5M | $245M | $217M | $206M |
| Operating income | β$58.2M | β$53.8M | β$80.0M | β$137M | β$176M | β$199M | β$320M | β$388M | β$324M | β$62.8M |
| Interest expense | $4.7M | $4.4M | $9.8M | $18.8M | $19.1M | $19.7M | $11.0M | $11.3M | $11.2M | $10.7M |
| Pretax income | β$57.6M | β$58.4M | β$102M | β$146M | β$189M | β$217M | β$331M | β$376M | β$321M | β$49.3M |
| Income tax | β$9.7M | $1.4M | $0.8M | β$0.0M | β$19.4M | $0.4M | $0.3M | $0.2M | $0.1M | $1.0M |
| Net income | β$47.9M | β$59.7M | β$103M | β$146M | β$169M | β$180M | β$278M | β$111M | β$322M | β$25.5M |
| Net income to common | β | β | β | β$146M | β$169M | β$180M | β$278M | β$111M | β$322M | β$25.5M |
| Diluted EPS | β$1.29 | β$1.54 | β$2.54 | β$3.46 | β$3.56 | β$3.01 | β$4.37 | β$1.50 | β$4.08 | β$0.29 |
| Diluted shares | 0.04B | 0.04B | 0.04B | 0.04B | 0.05B | 0.06B | 0.06B | 0.07B | 0.08B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | β$3.4M | $7.4M | β$25.0M | β$58.2M | β$42.7M | β$14.8M | β$186M | β$280M | β$237M | $37.8M |
| Capital expenditure | $1.4M | $0.9M | $0.7M | $0.2M | $6.8M | $5.1M | $0.2M | $0.7M | β | β |
| Free cash flow | β$4.9M | $6.5M | β$25.7M | β$58.4M | β$49.5M | β$19.9M | β$186M | β$281M | β | β |
| Depreciation and amortization | $16.1M | $17.8M | $18.7M | $20.4M | $24.6M | $12.7M | $20.7M | $38.5M | $43.6M | $60.7M |
| Stock-based compensation | $29.1M | $26.9M | $19.8M | $21.1M | $23.6M | $29.6M | $38.1M | $44.2M | $36.9M | $44.9M |
| Acquisitions | $0.6M | $0.0M | $0.0M | $0.0M | $95.3M | $0.0M | $0.0M | β | β | β |
| Share buybacks | $0.0M | β | β | β | β | β | β | β | β | β |
| Dividends and buybacks | $0.0M | β | β | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $41.0M | $223M | $311M | $272M | $357M | $428M | $347M | $307M | $58.5M | $238M |
| Current assets | $332M | $326M | $496M | $429M | $410M | $583M | $486M | $617M | $417M | $438M |
| Current liabilities | $83.3M | $85.7M | $105M | $95.4M | $92.7M | $124M | $142M | $178M | $201M | $160M |
| Inventory | $2.8M | $5.4M | $5.6M | $6.1M | $7.6M | $7.3M | $4.5M | $9.4M | $41.9M | $36.2M |
| Property and equipment, net | $2.6M | $3.2M | $3.1M | $2.9M | $9.4M | $11.1M | $9.0M | $7.5M | $5.3M | $4.0M |
| Goodwill | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.9M | $0.8M | $0.8M | $0.8M | β |
| Intangible assets | $182M | $185M | $187M | $157M | $154M | $148M | $97.1M | $104M | $104M | $114M |
| Total assets | $525M | $520M | $709M | $605M | $607M | $777M | $673M | $789M | $594M | $605M |
| Total liabilities | $218M | $227M | $391M | $384M | $396M | $475M | $630M | $588M | $535M | $490M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $308M | $293M | $318M | $221M | $211M | $302M | $42.9M | $201M | $59.1M | $115M |
| Margins | ||||||||||
| Gross margin | 96.6% | 97.7% | 96.6% | 97.0% | 96.9% | 97.1% | 96.0% | 92.1% | 96.7% | 97.9% |
| Operating margin | β43.6% | β34.7% | β48.7% | β78.3% | β88.8% | β151.3% | β292.2% | β267.2% | β138.9% | β12.8% |
| EBITDA margin | β31.5% | β23.2% | β37.4% | β66.7% | β76.4% | β141.6% | β273.2% | β240.7% | β120.2% | β0.4% |
| Net margin | β35.9% | β38.6% | β62.5% | β83.5% | β85.4% | β136.6% | β254.4% | β76.7% | β137.9% | β5.2% |
| FCF margin | β3.6% | 4.2% | β15.6% | β33.3% | β25.0% | β15.1% | β170.4% | β193.3% | β | β |
| Net interest share of revenue | 3.0% | 2.1% | 3.3% | β | β | β | β | β | β | β |
| Returns | ||||||||||
| Return on capital employed | β13.2% | β12.4% | β13.2% | β27.0% | β34.2% | β30.6% | β60.3% | β63.5% | β82.3% | β14.1% |
| Return on equity | β15.6% | β19.9% | β33.6% | β54.3% | β78.4% | β70.2% | β161.5% | β91.4% | β247.4% | β29.4% |
| Return on assets | β9.1% | β11.4% | β16.7% | β22.3% | β28.0% | β26.0% | β38.4% | β15.2% | β46.5% | β4.3% |
| Return on tangible equity | β38.4% | β55.6% | β78.6% | β232.2% | β301.5% | β117.9% | β | β116.6% | β | β2,661.0% |
| Growth | ||||||||||
| Revenue growth | β | 16.0% | 6.0% | 6.8% | 13.1% | β33.5% | β17.0% | 32.7% | 60.5% | 110.5% |
| FCF growth | β | β | β494.2% | β | β | β | β | β | β | β |
| Share count change | β | 1.3% | 4.3% | 4.7% | 12.3% | 25.9% | 6.6% | 16.5% | 6.2% | 13.1% |
| Financial health | ||||||||||
| Interest coverage | β12.3x | β12.2x | β8.2x | β7.3x | β9.2x | β10.1x | β29.1x | β34.3x | β29.0x | β5.8x |
| Current ratio | 4.0x | 3.8x | 4.7x | 4.5x | 4.4x | 4.7x | 3.4x | 3.5x | 2.1x | 2.7x |
| Quick ratio | 4.0x | 3.7x | 4.7x | 4.4x | 4.3x | 4.6x | 3.4x | 3.4x | 1.9x | 2.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.1% | 0.6% | 0.4% | 0.1% | 3.4% | 3.9% | 0.2% | 0.5% | β | β |
| Stock comp / revenue | 21.8% | 17.3% | 12.0% | 12.0% | 11.9% | 22.4% | 34.8% | 30.5% | 15.8% | 9.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 2.0 | 3.0 | 2.0 | 4.0 | 1.0 | 3.0 | 3.0 | 6.0 |
| Altman Z'' | 3.2 | 2.6 | 2.5 | 0.5 | β1.1 | β0.4 | β4.7 | β3.9 | β9.1 | β5.4 |
| Accruals ratio | β8.5% | β12.8% | β12.6% | β13.4% | β20.9% | β23.9% | β12.7% | 23.1% | β12.2% | β10.6% |
Source: SEC EDGAR XBRL filings (CIK 0001438533). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
